{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:43:45Z","timestamp":1791413025530,"version":"4.3.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,9]]},"DOI":"10.7759\/cureus.78761","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T11:35:31Z","timestamp":1739100931000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Nemolizumab in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Kunal","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeharika","family":"Muppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeela","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keron","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: epidemiology and clinical features","volume":"83","author":"Huang AH","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020, 83:1559-65. 10.1016\/j.jaad.2020.04.183","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga M","year":"2022","unstructured":"Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. Allergol Int. 2022, 71:265-77. 10.1016\/j.alit.2022.04.003","journal-title":"Allergol Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis","volume":"14","author":"Williams KA","year":"2021","unstructured":"Williams KA, Roh YS, Brown I, et al.. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021, 14:67-77. 10.1080\/17512433.2021.1852080","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2020.07.002","article-title":"Pruritus in black skin: unique molecular characteristics and clinical features","volume":"113","author":"McColl M","year":"2021","unstructured":"McColl M, Boozalis E, Aguh C, Eseonu AC, Okoye GA, Kwatra SG. Pruritus in black skin: unique molecular characteristics and clinical features. J Natl Med Assoc. 2021, 113:30-8. 10.1016\/j.jnma.2020.07.002","journal-title":"J Natl Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/12034754231211797","article-title":"Systemic medication for the treatment of prurigo nodularis-a systematic review","volume":"27","author":"McCampbell LE","year":"2023","unstructured":"McCampbell LE, Zaino ML, Ranpariya M, Patel T, Feldman SR. Systemic medication for the treatment of prurigo nodularis-a systematic review. J Cutan Med Surg. 2023, 27:641-5. 10.1177\/12034754231211797","journal-title":"J Cutan Med Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241227634","article-title":"Non-systemic medication for the treatment of prurigo nodularis: a systematic review","volume":"28","author":"Ranpariya M","year":"2024","unstructured":"Ranpariya M, Zaino ML, McCampbell LE, Patel T, Feldman SR. Non-systemic medication for the treatment of prurigo nodularis: a systematic review. J Cutan Med Surg. 2024, 28:173-7. 10.1177\/12034754241227634","journal-title":"J Cutan Med Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000001010","article-title":"Novel therapeutic receptor agonists and antagonists in allergic conjunctivitis","volume":"24","author":"Abu SL","year":"2024","unstructured":"Abu SL, Hehar NK, Chigbu DI. Novel therapeutic receptor agonists and antagonists in allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2024, 24:380-9. 10.1097\/ACI.0000000000001010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2306225","article-title":"A critical evaluation of nemolizumab for prurigo nodularis","volume":"20","author":"Brooks SG","year":"2024","unstructured":"Brooks SG, Yosipovitch G. A critical evaluation of nemolizumab for prurigo nodularis. Expert Rev Clin Immunol. 2024, 20:577-87. 10.1080\/1744666X.2024.2306225","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder S","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al.. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020, 382:706-16. 10.1056\/NEJMoa1908316","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023, 389:1579-89. 10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of Nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","author":"St\u00e4nder S","year":"2024","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al.. Efficacy and safety of Nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial. JAMA Dermatol. 2024, 10.1001\/jamadermatol.2024.4796","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a\u00a0randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13\u2005years","volume":"191","author":"Yokozeki H","year":"2024","unstructured":"Yokozeki H, Murota H, Matsumura T, Komazaki H. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a\u00a0randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13\u2005years. Br J Dermatol. 2024, 191:200-8. 10.1093\/bjd\/ljae131","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.12.014","article-title":"Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis","volume":"113","author":"Serra-Baldrich E","year":"2022","unstructured":"Serra-Baldrich E, Santamar\u00eda-Bab\u00ed LF, Francisco Silvestre J. Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis. Actas Dermosifiliogr. 2022, 113:674-84. 10.1016\/j.ad.2021.12.014","journal-title":"Actas Dermosifiliogr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-024-01436-9","article-title":"A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis","volume":"32","author":"Nilforoushzadeh MA","year":"2024","unstructured":"Nilforoushzadeh MA, Heidari N, Ghane Y, et al.. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis. Inflammopharmacology. 2024, 32:991-1003. 10.1007\/s10787-024-01436-9","journal-title":"Inflammopharmacology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi LC","year":"2022","unstructured":"Tsoi LC, Hacini-Rachinel F, Fogel P, et al.. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol. 2022, 149:1329-39. 10.1016\/j.jaci.2021.10.004","journal-title":"J Allergy Clin Immunol"},{"key":"ref16","unstructured":"Regeneron Pharmaceuticals. Accessed. 5 Jan 2025: https:\/\/www.dupixenthcp.com."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.10.011","article-title":"Cluster analysis of circulating plasma biomarkers in prurigo nodularis reveals a distinct systemic inflammatory signature in African Americans","volume":"142","author":"Sutaria N","year":"2022","unstructured":"Sutaria N, Alphonse MP, Marani M, et al.. Cluster analysis of circulating plasma biomarkers in prurigo nodularis reveals a distinct systemic inflammatory signature in African Americans. J Invest Dermatol. 2022, 142:1300-1308.e3. 10.1016\/j.jid.2021.10.011","journal-title":"J Invest Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima K","year":"2018","unstructured":"Kabashima K, Furue M, Hanifin JM, et al.. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018, 142:1121-1130.e7. 10.1016\/j.jaci.2018.03.018","journal-title":"J Allergy Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies","volume":"186","author":"Kabashima K","year":"2022","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2022, 186:642-51. 10.1111\/bjd.20873","journal-title":"Br J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336895-efficacy-and-safety-of-nemolizumab-in-patients-with-prurigo-nodularis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T11:35:33Z","timestamp":1739100933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336895-efficacy-and-safety-of-nemolizumab-in-patients-with-prurigo-nodularis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.78761","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,9]]}}}